Biogen Idec (NASDAQ:BIIB), Fondazione Telethon and Ospedale San Raffaele have entered into a worldwide collaboration to jointly develop gene therapies for the treatment of both hemophilia A and B.

The agreement will combine San Raffaele - Telethon Institute for Gene Therapy's (TIGET) extensive expertise in creating new gene therapy strategies and developing them from the bench to bedside with Biogen Idec's deep understanding of hematology to potentially treat the underlying causes of hemophilia A and B.

Read more

Source: http://pipelinereview.com/